home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 04/15/24

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We...
IMMX - IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

2024-04-02 07:53:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immix Biopharma (NASDAQ: IMMX ) just reported results for the fourth quarter of 2023. Immix Biopharma reported earnings per share of -24 cents. This was below the analyst ...

IMMX - Expected US Company Earnings on Monday, April 1st, 2024

GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...

IMMX - Expected US Company Earnings on Monday, March 25th, 2024

Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
IMMX - Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis ...

IMMX - Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis ...

IMMX - Immix Biopharma 12 Month Review Progress Update

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. “The past 12 months have ...
IMMX - InvestorNewsBreaks - Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX) , a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at ...

IMMX - Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology,...

IMMX - Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU protocol assistance, marketing authorization applications, inspections befo...
Previous 10 Next 10